文献

重组抗小鼠PD-1单克隆抗体(克隆号29F.1A12.1) ，大鼠IgG2a Kappa（Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone: 29F.1A12.1), Rat IgG2a Kappa，货号：PA007505.r2a Syd Labs）

大鼠抗小鼠PD-1单克隆抗体29F.1A12（大鼠IgG2a kappa）可与由小鼠Pdcd1基因编码的小鼠PD-1蛋白（程序性死亡-1或CD279）发生反应，该蛋白是免疫球蛋白超家族CD28家族的成员。PD-1有两个配体即PD-L1和PD-L2，二者均属于B7家族。研究表明，在黑色素瘤小鼠模型中，通过抗小鼠PD-1和抗小鼠PD-L1抗体进行治疗可以阻断PD-L1蛋白与其受体PD-1蛋白之间的相互作用，从而使肿瘤生长得到暂时性抑制。29F.1A12单克隆抗体能够阻断小鼠PD-L1蛋白和小鼠PD-L2蛋白与小鼠PD-1蛋白的结合。我们的重组29F.1A12抗体包含大鼠抗小鼠PD-1单克隆抗体（杂交瘤克隆名称或编号：29F.1A12）的部分（可变区）或完整的氨基酸序列。

29F.1A12抗体（CD279抗体、抗小鼠PD1单抗）流式部分参考文献:

1. Anti-PD-1 therapy triggers Tfh cell–dependent IL-4 release to boost CD8 T cell responses in tumor-draining lymph nodes.
Ruggiu, M., et al. J Exp Med. 2024;221(4):e20232104. PMID: 38417020
“Lymph node cells were stained ex vivo with a different anti-PD-1 mAb clone that did not interfere with the injected mAb (Polesso et al., 2021) to link in vivo labeling with PD-1 surface expression levels. …(B) Representative FACS dot plot showing in vivo labeling by AF594-labeled anti-PD-1 mAb (clone RMP1-14) and ex vivo staining by anti-PD-1 antibody (clone 29F.1A12). …anti-mouse PD1-BX036 (purified clone 29F.1A12 from…”

2. Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells.
Martins, C., et al. Sci Rep. 2022;12(1):12491. PMID: 35864188
“Similarly, in preclinical cancer models, several PD-1 blocking ab clones, including 29F.1A12 (anti-mouse PD-1 antibody), thwart tumor progression 4 , 5 , 6 , 7 , 8. …For example, TME-infiltrating macrophages and natural killer (NK) cells both express PD-1, the blockade of which by 29F.1A12 (anti-mouse PD-1 mAb) contributes to tumor growth suppression and prolonged survival 10 , 11. …29F.1A12 antibody recognizes PD-1 on B16-F10 and other murine tumor lines, suppresses cancer cell-intrinsic PD-1 receptor signaling, and inhibits resultant tumor growth in three-dimensional (3D) culture and tumor-bearing mice 5 , 7…”

3. Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Metzger, P., et al. Sci Rep. 2018;8(1):9040. PMID: 29892077
“In addition, PD-1 staining (clone 29F1A12) uncovered a FSC-H low population predominantly positive for PD-1. …PD-1 (clone 29F.1A12) and fixable viability dye (FVD) staining was assessed by flow cytometry. …PD-1 staining (clone 29F.1A12) in these cells could be due to binding of an intracellular PD-1 pool that becomes accessible in cells with leaky membranes…Again, PD-1 mAb staining (clone 29F.1A12) was found in both PD-1 wild-type and knock-out cells in the dead cell fraction, indicative of unspecific binding. …We assessed PD-1 expression by flow cytometry and compared the two mainly used antibody clones (29F.1A12 and RMP1-14), which were also included in the above-mentioned study.”

4. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Koyama, S., et al. Nat Commun. 2016;7:10501. PMID: 26883990
“Fluorescent conjugated anti-PD-1 antibody is the same clone (29F.1A12) as the therapeutic antibody. …PD-1-blocking antibody (clone 29F.1A12), TIM-3-blocking antibody (clone RMT3-23) and their isotype controls (clone 2A3) were injected intraperitoneally into the mice for therapeutic treatment (three times a week, 200 µg for PD1 and 100 µg for TIM-3 per dose).”

5. The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection.
Pauken, K. E., et al. Cell Rep. 2020;31(13):107827. PMID: 32610128
“WT B6 mice were treated with anti-PD-1 antibody (clone 29F.1A12) or isotype control antibody (rat IgG2a) on days -1, 2, and 5 and harvested on day 8 p.i., or treated on days -1, 2, 5, and 8 and harvested on day 60+ p.i. PD-L1/L2 DKO mice were included as a control. …For in vivo antibody blockade experiments, WT C57BL/6 mice were given 200 µg per mouse per injection of rat anti-PD-1 antibody (clone 29F.1A12) or isotype control antibody (Rat IgG2a, clone 2A3) on days -1, 2, and 5 p.i. and analyzed at day 8 p.i., or on days -1, 2, 5, and 8 p.i. and analyzed at day 60+ p.i…”